Interaction of pain and chronic inflammation; [Wechselwirkungen von Schmerz und chronischer Entzündung]

被引:0
作者
Seifert O. [1 ]
Baerwald C. [1 ]
机构
[1] Klinik für Endokrinologie, Nephrologie und Rheumatologie, Universitätsklinikum Leipzig AöR, Liebigstr. 20, Leipzig
关键词
Central sensitization; Cytokines; Hyperalgesia; Neuroimmunomodulation; Rheumatic diseases;
D O I
10.1007/s00393-020-00951-8
中图分类号
学科分类号
摘要
Rheumatic diseases are characterized by chronic inflammation of synovial joints and are often associated with persistent pain and increased pain sensitivity. The inflammatory process is a complex cascade of events involving several mediators, which can lead to a chronic condition of pain. Inflammation can stimulate angiogenesis, and angiogenesis can facilitate inflammation. Inflammatory pain arises from tissue damage via the sensitization of pain receptors (nociceptors). The main peripheral mechanism underlying nociceptive pain is a change in the activity of the nociceptors located in the affected anatomical structures (joints, tendons, and ligaments), which renders them more sensitive to normally painful stimuli (hyperalgesia) or normally non-painful stimuli (allodynia). Neuroimmune interaction has been considered to play an essential role in rheumatic disease. Neurogenic inflammation, which influences normal central nervous system signaling, leads to insufficient signaling/bioavailability of various cytokines. These central mechanisms play an important role in the increased pain sensitivity following inflammation and are responsible for the development of secondary hyperalgesia in regions beyond the injured tissue. Reduction of pain in rheumatic disease requires familiarity with various pain mechanisms. © 2021, Springer Medizin Verlag GmbH, ein Teil von Springer Nature.
引用
收藏
页码:205 / 213
页数:8
相关论文
共 30 条
  • [21] Riedel W., Neeck G., Nociception, pain, and antinociception: current concepts, Z Rheumatol, 60, 6, pp. 404-415, (2001)
  • [22] Rifbjerg-Madsen S., Christensen A.W., Christensen R., Et al., Pain and pain mechanisms in patients with inflammatory arthritis: a Danish nationwide cross-sectional DANBIO registry survey, PLoS ONE, 12, 7, (2017)
  • [23] Sarzi-Puttini P., Atzeni F., Salaffi F., Pain in rheumatic diseases: how relevant is it?, Reumatismo, 66, 1, pp. 1-3, (2014)
  • [24] Seidel M.F., Herguijuela M., Forkert R., Et al., Nerve growth factor in rheumatic diseases, Semin Arthritis Rheum, 40, 2, pp. 109-126, (2010)
  • [25] Straub R.H., Bijlsma J.W., Masi A., Et al., Role of neuroendocrine and neuroimmune mechanisms in chronic inflammatory rheumatic diseases—the 10-year update, Semin Arthritis Rheum, 43, 3, pp. 392-404, (2013)
  • [26] Syx D., Tran P.B., Miller R.E., Et al., Peripheral mechanisms contributing to osteoarthritis pain, Curr Rheumatol Rep, 20, 2, (2018)
  • [27] Walsh D.A., McWilliams D.F., Mechanisms, impact and management of pain in rheumatoid arthritis, Nat Rev Rheumatol, 10, 10, pp. 581-592, (2014)
  • [28] Yousefi B., Jadidi-Niaragh F., Azizi G., The role of leukotrienes in immunopathogenesis of rheumatoid arthritis, Mod Rheumatol, 24, 2, pp. 225-2235, (2014)
  • [29] Zhang A., Lee Y.C., Mechanisms for joint pain in rheumatoid arthritis (RA): from cytokines to central sensitization, Curr Osteoporos Rep, 16, 5, pp. 603-610, (2018)
  • [30] Zheng L.X., Li K.X., Hong F.F., Pain and bone damage in rheumatoid arthritis: role of leukotriene B4, Clin Exp Rheumatol, 37, 5, pp. 872-878, (2019)